Definium Therapeutics (NASDAQ:DFTX) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Definium Therapeutics from “sell” to “hold.” Overall, analysts rate the stock “Moderate Buy,” with an average price target of $66.24; ratings include 19 Buys, one Strong Buy, and one Sell.
• The company reported a quarterly loss of $0.46 per share, beating analysts’ estimate of a $0.55 loss. Shares opened at $32.08, within a 12-month range of $10.46 to $49.70.
• Insiders sold about 71,100 shares worth $2.63 million over the past 90 days, while institutional investors own 27.91% of the stock.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday, Wall Street Zen reports.

A number of other research firms have also recently commented on DFTX. Wells Fargo & Company increased their target price on shares of Definium Therapeutics from $68.00 to $72.00 and gave the stock an "overweight" rating in a report on Thursday, August 13th. Canaccord Genuity Group set a $78.00 price target on shares of Definium Therapeutics and gave the company a "buy" rating in a report on Tuesday, September 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Definium Therapeutics in a research report on Thursday, October 15th. UBS Group reiterated a "buy" rating and set a $70.00 price objective on shares of Definium Therapeutics in a research report on Tuesday, September 15th. Finally, Oppenheimer reissued an "outperform" rating and issued a $75.00 price objective on shares of Definium Therapeutics in a research note on Monday, September 14th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Definium Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $66.24.

Definium Therapeutics Price Performance

Shares of DFTX stock opened at $32.08 on Friday. The company has a quick ratio of 6.95, a current ratio of 15.53 and a debt-to-equity ratio of 0.04. Definium Therapeutics has a twelve month low of $10.46 and a twelve month high of $49.70. The company has a market cap of $4.31 billion, a P/E ratio of -10.32 and a beta of 2.23. The business has a fifty day simple moving average of $36.07 and a 200 day simple moving average of $30.38.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.09. On average, sell-side analysts forecast that Definium Therapeutics will post -2.94 EPS for the current fiscal year.

Insider Transactions at Definium Therapeutics

In other news, insider Matthew T. Wiley sold 3,097 shares of Definium Therapeutics stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $113,257.29. Following the sale, the insider directly owned 359,036 shares of the company's stock, valued at approximately $13,129,946.52. This trade represents a 0.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the business's stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $1,153,783.50. Following the sale, the chief executive officer owned 2,213,090 shares in the company, valued at approximately $80,932,701.30. This trade represents a 1.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 71,098 shares of company stock worth $2,626,115 in the last 90 days. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP bought a new stake in Definium Therapeutics during the 2nd quarter worth approximately $138,755,000. Bank of New York Mellon Corp increased its position in Definium Therapeutics by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company's stock valued at $36,563,000 after acquiring an additional 24,349 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Definium Therapeutics by 116.1% during the third quarter. Russell Investments Group Ltd. now owns 331,702 shares of the company's stock valued at $12,647,000 after acquiring an additional 178,225 shares during the last quarter. Royce & Associates LP raised its stake in shares of Definium Therapeutics by 20.1% during the third quarter. Royce & Associates LP now owns 250,547 shares of the company's stock valued at $9,536,000 after acquiring an additional 41,996 shares during the last quarter. Finally, Aberdeen Group plc raised its stake in shares of Definium Therapeutics by 10.0% during the third quarter. Aberdeen Group plc now owns 192,415 shares of the company's stock valued at $7,323,000 after acquiring an additional 17,415 shares during the last quarter. Institutional investors own 27.91% of the company's stock.

About Definium Therapeutics

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.